NICE recommends Opdivo-Yervoy combo

In final guidance released Wednesday, the U.K.'s NICE recommended Opdivo nivolumab in combination with Yervoy ipilimumab to treat advanced melanoma. NICE said it completed its appraisal 24 working days after the combo received marketing authorization, making the appraisal its fastest ever in cancer.

The recommendation is contingent on a discounted patient access scheme for Yervoy. ...